Physician profile
Jay S Meyerowitz
NPI 1891892816
$3,398.58
in general payments reported to CMS, 2019-2025
41 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Geriatric Medicine (Internal Medicine) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,124 · 2020: $367 · 2021: $701 · 2022: $244 · 2023: $334 · 2024: $345 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $962.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $320.18 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $316.07 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $283.19 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Amgen INC. | $250.74 | 2019-2024 | Evenity, Prolia |
| Avanir Pharmaceuticals, INC. | $221.29 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $195.12 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $187.04 | 2019-2021 | |
| Biogen, INC. | $99.17 | 2021-2022 | |
| Lilly USA, LLC | $98.77 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Jazz Pharmaceuticals INC. | $98.60 | 2019-2020 | |
| Lundbeck LLC | $98.54 | 2024-2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $94.78 | 2024-2025 | Belbuca |
| Insmed, INC. | $84.24 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $83.52 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $73.81 | 2024-2025 | Rexulti |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Meyerowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.